Boston Scientific Retained Earnings (Accumulated Deficit) 2010-2025 | BSX
Boston Scientific retained earnings (accumulated deficit) from 2010 to 2025. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- Boston Scientific retained earnings (accumulated deficit) for the quarter ending March 31, 2025 were $3.347B, a 154.72% increase year-over-year.
- Boston Scientific retained earnings (accumulated deficit) for 2024 were $2.673B, a 226.37% increase from 2023.
- Boston Scientific retained earnings (accumulated deficit) for 2023 were $0.819B, a 209.2% decline from 2022.
- Boston Scientific retained earnings (accumulated deficit) for 2022 were $-0.75B, a 46.12% decline from 2021.
| Boston Scientific Annual Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2024 | $2,673 |
| 2023 | $819 |
| 2022 | $-750 |
| 2021 | $-1,392 |
| 2020 | $-2,378 |
| 2019 | $-2,253 |
| 2018 | $-6,953 |
| 2017 | $-8,390 |
| 2016 | $-8,581 |
| 2015 | $-8,927 |
| 2014 | $-8,689 |
| 2013 | $-8,570 |
| 2012 | $-8,449 |
| 2011 | $-4,381 |
| 2010 | $-4,822 |
| 2009 | $-3,757 |
| Boston Scientific Quarterly Retained Earnings (Accumulated Deficit) (Millions of US $) |
|
|---|---|
| 2025-03-31 | $3,347 |
| 2024-12-31 | $2,673 |
| 2024-09-30 | $2,107 |
| 2024-06-30 | $1,639 |
| 2024-03-31 | $1,314 |
| 2023-12-31 | $819 |
| 2023-09-30 | $315 |
| 2023-06-30 | $-189 |
| 2023-03-31 | $-450 |
| 2022-12-31 | $-750 |
| 2022-09-30 | $-876 |
| 2022-06-30 | $-1,050 |
| 2022-03-31 | $-1,296 |
| 2021-12-31 | $-1,392 |
| 2021-09-30 | $-1,473 |
| 2021-06-30 | $-1,878 |
| 2021-03-31 | $-2,050 |
| 2020-12-31 | $-2,378 |
| 2020-09-30 | $-2,574 |
| 2020-06-30 | $-2,405 |
| 2020-03-31 | $-2,252 |
| 2019-12-31 | $-2,253 |
| 2019-09-30 | $-6,249 |
| 2019-06-30 | $-6,375 |
| 2019-03-31 | $-6,528 |
| 2018-12-31 | $-6,953 |
| 2018-09-30 | $-7,339 |
| 2018-06-30 | $-7,770 |
| 2018-03-31 | $-8,326 |
| 2017-12-31 | $-8,390 |
| 2017-09-30 | $-7,785 |
| 2017-06-30 | $-8,068 |
| 2017-03-31 | $-8,215 |
| 2016-12-31 | $-8,581 |
| 2016-09-30 | $-8,706 |
| 2016-06-30 | $-8,934 |
| 2016-03-31 | $-8,725 |
| 2015-12-31 | $-8,927 |
| 2015-09-30 | $-8,785 |
| 2015-06-30 | $-8,587 |
| 2015-03-31 | $-8,690 |
| 2014-12-31 | $-8,689 |
| 2014-09-30 | $-8,389 |
| 2014-06-30 | $-8,432 |
| 2014-03-31 | $-8,436 |
| 2013-12-31 | $-8,570 |
| 2013-09-30 | $-8,678 |
| 2013-06-30 | $-8,673 |
| 2013-03-31 | $-8,803 |
| 2012-12-31 | $-8,449 |
| 2012-09-30 | $-8,510 |
| 2012-06-30 | $-7,846 |
| 2012-03-31 | $-4,268 |
| 2011-12-31 | $-4,381 |
| 2011-09-30 | $-4,488 |
| 2011-06-30 | $-4,630 |
| 2011-03-31 | $-4,776 |
| 2010-12-31 | $-4,822 |
| 2010-09-30 | $-5,058 |
| 2010-06-30 | $-5,248 |
| 2010-03-31 | $-5,346 |
| 2009-12-31 | $-3,757 |
| 2009-09-30 | $-2,681 |
| 2009-06-30 | $-2,588 |
| 2009-03-31 | $-2,745 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $157.798B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $235.835B | 28.36 |
| Stryker (SYK) | United States | $150.649B | 31.50 |
| EssilorLuxottica (ESLOY) | France | $134.205B | 0.00 |
| Medtronic (MDT) | Ireland | $111.543B | 16.29 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.908B | 0.00 |
| Haleon (HLN) | United Kingdom | $49.033B | 27.90 |
| ResMed (RMD) | United States | $37.148B | 27.90 |
| GE HealthCare Technologies (GEHC) | United States | $33.471B | 15.89 |
| Agilent Technologies (A) | United States | $32.342B | 21.36 |
| Terumo (TRUMY) | Japan | $27.583B | 35.83 |
| Insulet (PODD) | United States | $22.931B | 90.01 |
| Koninklijke Philips (PHG) | Netherlands | $22.436B | 16.13 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.948B | 12.17 |
| Baxter (BAX) | United States | $16.150B | 12.06 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.745B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $8.231B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.767B | 23.55 |
| Lantheus Holdings (LNTH) | United States | $5.414B | 13.66 |
| Prestige Consumer Healthcare (PBH) | United States | $4.395B | 19.63 |
| Perrigo (PRGO) | Ireland | $3.739B | 9.48 |
| Haemonetics (HAE) | United States | $3.484B | 15.18 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.396B | 25.05 |
| Envista Holdings (NVST) | United States | $3.000B | 24.93 |
| QuidelOrtho (QDEL) | United States | $2.203B | 15.15 |
| GN Store Nord (GNNDY) | Denmark | $2.097B | 17.37 |
| LeMaitre Vascular (LMAT) | United States | $1.942B | 43.41 |
| AtriCure (ATRC) | United States | $1.604B | 0.00 |
| Neogen (NEOG) | United States | $1.389B | 17.78 |
| Kestra Medical Technologies (KMTS) | United States | $1.245B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.213B | 12.31 |
| Green Thumb Industries (GTBIF) | United States | $1.175B | 26.43 |
| BioLife Solutions (BLFS) | United States | $1.090B | 0.00 |
| InMode (INMD) | Israel | $1.011B | 9.25 |
| Phibro Animal Health (PAHC) | United States | $0.978B | 12.50 |
| CeriBell (CBLL) | United States | $0.644B | 0.00 |
| Evolus (EOLS) | United States | $0.638B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.566B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.553B | 0.00 |
| Owens & Minor (OMI) | United States | $0.548B | 4.54 |
| Valneva SE (VALN) | France | $0.530B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.474B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.456B | 0.00 |
| Surmodics (SRDX) | United States | $0.422B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.349B | 0.00 |
| SNDL (SNDL) | Canada | $0.342B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.330B | 12.14 |
| Canopy Growth (CGC) | Canada | $0.302B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.300B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.282B | 50.20 |
| Sanara MedTech (SMTI) | United States | $0.277B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.267B | 22.50 |
| Sanuwave Health (SNWV) | United States | $0.253B | 0.00 |
| Cerus (CERS) | United States | $0.252B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.250B | 0.00 |
| ZimVie (ZIMV) | United States | $0.244B | 11.08 |
| Biote (BTMD) | United States | $0.222B | 6.25 |
| Brainsway (BWAY) | Israel | $0.201B | 53.25 |
| OraSure Technologies (OSUR) | United States | $0.197B | 0.00 |
| Omeros (OMER) | United States | $0.195B | 0.00 |
| High Tide (HITI) | Canada | $0.190B | 0.00 |
| Quanterix (QTRX) | United States | $0.189B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.177B | 14.41 |
| Organigram Global (OGI) | Canada | $0.175B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.167B | 0.00 |
| Exagen (XGN) | United States | $0.135B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.130B | 15.94 |
| Jin Medical (ZJYL) | China | $0.126B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.116B | 0.00 |
| Agape ATP (ATPC) | $0.102B | 0.00 | |
| MacroGenics (MGNX) | United States | $0.100B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Fonar (FONR) | United States | $0.084B | 10.81 |
| Veru (VERU) | United States | $0.076B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.073B | 0.00 |
| InterCure (INCR) | Israel | $0.072B | 0.00 |
| Zynex (ZYXI) | United States | $0.071B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.060B | 0.00 |
| United Health Products (UEEC) | United States | $0.058B | 0.00 |
| Apyx Medical (APYX) | United States | $0.056B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.053B | 0.00 |
| ImmuCell (ICCC) | United States | $0.050B | 0.00 |
| Modular Medical (MODD) | United States | $0.040B | 0.00 |
| United-Guardian (UG) | United States | $0.040B | 13.69 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Safety Shot (SHOT) | United States | $0.030B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.023B | 0.00 |
| Nephros (NEPH) | United States | $0.023B | 30.71 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.008B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Acuren (TIC) | United States | $0.000B | 0.00 |